As shown in Table 2, there were no significant differences between the adjuvant therapy and non-adjuvant therapy groups in age (P = 0.073), gender (P = 0.711), BMI (P = 0.764), albumin (P = 0.329), ALT (P = 0.607), AST (P = 0.642), CA19-9 (P = 0.072), CA125 (P = 0.349), pathological type (P = 0.527), margin status (P = 0.839), microvascular invasion (P = 0.704), lymph node metastasis (P = 0.452), differentiation degree (P = 0.855), or TNM stage (P = 0.206). The gene discussed is ALB; the disease is metastatic malignant neoplasm in the lymph nodes.